Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,588 Mln
Revenue (TTM)
$5 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.8
Industry P/E
--
EV/EBITDA
-13.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$10.6
EPS
$-5
Face value
--
Shares outstanding
104,705,330
CFO
$-512.91 Mln
EBITDA
$-665.32 Mln
Net Profit
$-645.89 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
| -20.0 | -9.4 | -20.0 | 21.6 | 32.3 | 18.4 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
| -9.0 | 43.3 | 94.4 | -35.6 | 101.3 | -43.8 | -16.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
|
37.2 | 3,588.3 | 7.7 | -465.3 | -9,331.0 | -40.2 | -- | 3.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product... candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 6055 Lusk Boulevard, San Diego, CA, United States, 92121 Read more
Founder, President, CEO & Director
Dr. R. Scott Struthers Ph.D.
Founder, President, CEO & Director
Dr. R. Scott Struthers Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Crinetics Pharmaceuticals Inc (CRNX) is $37.23 (NASDAQ) as of 02-Apr-2026 16:28 EDT. Crinetics Pharmaceuticals Inc (CRNX) has given a return of 32.35% in the last 3 years.
Since, TTM earnings of Crinetics Pharmaceuticals Inc (CRNX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.40
|
4.41
|
|
2024
|
-13.88
|
3.13
|
|
2023
|
-9.62
|
3.83
|
|
2022
|
-5.95
|
3.01
|
|
2021
|
-10.12
|
3.25
|
The 52-week high and low of Crinetics Pharmaceuticals Inc (CRNX) are Rs 57.99 and Rs 24.10 as of 04-Apr-2026.
Crinetics Pharmaceuticals Inc (CRNX) has a market capitalisation of $ 3,588 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Crinetics Pharmaceuticals Inc (CRNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.66
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.